【摘要】 目的评价瑞波西汀治疗抑郁症伴随焦虑症状的有效性。方法采用随机、双盲、双模拟、氟西汀平行对照、多中心临床研究的方法。入组汉密尔顿抑郁量表(HAMD)17项≥18分且汉密尔顿焦虑量表(HAMA)≥14分的抑郁伴焦虑患者共137例(意向性治疗数据集,ITT集),分为试验组67例和对照组70例;完成试验132例(符合方案数据集,PP集),试验组64例,对照组68例。试验组每天服瑞波西汀8 mg,对照组每天服氟西汀20 mg。治疗时间为6 wk,在基线及治疗1、2、46、wk时评定HAMA、HAMD量表。结果根据PP集,治疗6 wk后,试验组和对照组HAMA减分值分别为(16.25±6.16)和(14.29±7.45)(P<0.05);治疗6 wk后,2组HAMD总分及因子分值变化在2组间无明显差异;2组不良反应无明显差异。结论瑞波西汀治疗抑郁伴随焦虑症状的作用有一定的优势;患者对瑞波西汀的耐受性好。更多还原

【Abstract】 AIM To evaluate the efficacy of reboxetine in the treatment of anxiety in depressive patients.METHODS To compare with fluoxetine,the randomized,double-blind,double-dummy clinical trial was designed for this study.There were 137 depressive patients were enrolled（Hamilton Rating Scale for Depression（HAMD）≥18 and Hamilton Anxiety Scale（HAMA）≥14）and 132 patients completed the whole therapy,64 patients in reboxetine group（study group）,68 in fluoxetine group（control group）.Patients in study group took reboxetine 8 mg·d^-1,and fluoxetine 20 mg·d^-1 in control group.The treatment duration was 6 wk.HAMA and HAMD were used to evaluate the symptoms in patients at baseline and wk 1,2,4 and 6.RESULTS The HAMA score reduction in study group was（16.25±6.16）and（（14.29±）7.45）in controll group after 6 wk（P=0.028 9）.There was significant difference between 2 groups.CONCLUSION Reboxetine is a safe and effective antidepressant in the treatment of anxiety in depressive patients.更多还原